A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy

NCT00936546 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

3

Enrollment

OTHER

Sponsor class

Conditions

Debilitating Fibrosing Skin Disorders (Localised Scleroderma, Eosinophilic Fasciitis)

Interventions

DRUG: Rituximab

Sponsor

University Hospital, Ghent